CBIH：释放大麻在未来医学中的潜力-动脉网

CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine

BioSpace 等信源发布 2024-07-08 21:50



可切换为仅中文







A letter from our desk

我们办公桌上的一封信

Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications..

德克萨斯州休斯顿（新闻文件公司，2024年7月8日）自年初以来，大麻生物科学国际控股公司（OTC Pink:CBIH）开始了一段变革之旅，涉及合并机会、专利注册和公司估值。随着我们进入下半年，我们的目标是解决和澄清我们之前沟通中的某些方面。。

From our desks - Rosangel Andrades and Jennifer Salguero.

来自我们的办公桌——罗桑格尔·安德拉德和詹妮弗·萨尔盖罗。

In the realm of medicine, patent requirements diverge from other forms of intellectual property, as clinical trials or studies are required to substantiate the attributes assigned to a compound.

在医学领域，专利要求与其他形式的知识产权不同，因为需要临床试验或研究来证实分配给化合物的属性。

While CBIH excels in bringing scientific rigor to the table, we acknowledge the imperative need for self-conducted studies. Our strategy unfolds in two primary directions. Initially, to amass comprehensive clinical evidence for our therapeutic interventions. Subsequently, to seize the opportunity presented by the impending declassification of cannabis, making clinical trials a focal point for numerous institutions and pharmaceutical entities.

虽然CBIH擅长将科学严谨性带到桌面上，但我们承认迫切需要进行自我研究。我们的战略主要有两个方向。最初，为我们的治疗干预积累全面的临床证据。随后，抓住即将解密大麻带来的机会，使临床试验成为众多机构和制药实体的焦点。

As we brace for the unfolding opportunities post-declassification, CBIH is strategically positioned to lead, thanks to our unique expertise as one of the limited clinical research units specializing exclusively in cannabis, thus, allowing us to generate additional revenues. This distinction would set us apart, given the scarcity of CRUs with comparable experience and understanding of cannabis clinical trials..

在我们为解密后即将出现的机会做好准备之际，CBIH凭借其独特的专业知识，成为专门从事大麻的有限临床研究单位之一，处于战略领先地位，从而使我们能够产生额外收入。鉴于缺乏对大麻临床试验具有可比经验和理解的CRU，这种区别将使我们与众不同。。

Moreover, we advocate for the utilization of provisional patents, which offer a 12-month grace period for conducting the requisite trials. These trials can encompass a variety of methodologies, including in vivo and in vitro preclinical studies, animal model testing, or leveraging single-cell studies..

此外，我们主张使用临时专利，为进行必要的试验提供12个月的宽限期。这些试验可以包括多种方法，包括体内和体外临床前研究，动物模型测试或利用单细胞研究。。

For more information on single cells studies, please visit: drive.google.com/file/d/1yuCVocWQqq1B6EqN1G5jlzy8g8LGuQSC/view?usp=sharing

有关单细胞研究的更多信息，请访问：drive.google.com/file/d/1yucvocwqqqq1b6eqn1g5jlzy8g8lguqsc/view？usp=共享

Furthermore, we intend to file all our patents with the United States Patent and Trademark Office (USPTO), targeting the lucrative U.S. market. This strategic filing not only strengthens our presence in the industry but also paves the way for collaborations with pharmaceutical companies exploring the potential of cannabinoid compounds.

此外，我们打算向美国专利商标局（USPTO）提交所有专利，目标是利润丰厚的美国市场。这一战略文件不仅加强了我们在该行业的影响力，而且为与制药公司合作探索大麻素化合物的潜力铺平了道路。

Our patent assets are poised to become a significant source of revenue. It's noteworthy that a 2019 Statista report indicated AbbVie's dominance with 59 cannabis patents, compared to Pfizer's 25. Given Pfizer's track record of striving for industry leadership, it's conceivable that they would be motivated to acquire more cannabis patents to assert their dominance in this emerging field..

我们的专利资产有望成为重要的收入来源。值得注意的是，2019年Statista的一份报告显示，AbbVie拥有59项大麻专利，而辉瑞只有25项。考虑到辉瑞在争取行业领先地位方面的记录，可以想象，他们会有动机获得更多大麻专利，以维护其在这一新兴领域的主导地位。。

In consequence, our objective is to tackle diseases that have been consistently overlooked and face a scarcity of effective treatments, such as menopause syndrome that could affect quite literally any woman in their lifespan, and Ewing cancer which is a severe and devastating condition that affects bones and soft tissue in adolescents.

因此，我们的目标是解决一直被忽视且缺乏有效治疗的疾病，例如更年期综合征，这可能会影响任何女性的寿命，以及尤因癌症，这是一种严重且毁灭性的疾病，会影响青少年的骨骼和软组织。

Our team is committed to addressing those neglected by conventional medical research..

我们的团队致力于解决那些被传统医学研究忽视的问题。。

From my desk - John Jones.

从我的桌子上——约翰·琼斯。

Evaluating our company's worth was a crucial move for our company, especially in light of potential merger and acquisition discussions. Identifying the right partner for such a significant endeavor remains our priority. Our goal transcends mere transactions; we seek a mutually beneficial partnership that thrives over time, making the selection of the perfect collaborator our greatest challenge.

评估我们公司的价值对我们公司来说是至关重要的一步，特别是考虑到潜在的并购讨论。为如此重大的努力找到合适的合作伙伴仍然是我们的首要任务。我们的目标超越了单纯的交易；我们寻求一种互利的伙伴关系，这种伙伴关系随着时间的推移而蓬勃发展，因此选择完美的合作者是我们最大的挑战。

Moreover, achieving a valuation of $2 billion is no small feat, it is a testament to the hard work, dedication, and innovative spirit of our team..

此外，实现20亿美元的估值是一项不小的壮举，它证明了我们团队的辛勤工作、奉献精神和创新精神。。

Our agreement with VITA Biotech Research has facilitated the receipt of the second installment of $50,000 for CBIH, catalyzing advancements in the marketing and development of our nutraceuticals.

我们与VITA Biotech Research的协议促进了CBIH第二笔50000美元的付款，促进了我们营养保健品营销和开发的进步。

Additionally, this partnership has facilitated our ability to register trademarks for our product names, which will be sold as dietary supplements, nutraceuticals, or vitamins, adhering to local regulations. This strategic move holds significant value for our company, as certain vitamins, such as our Cancer VITA or Precancer VITA, could exert a remarkable influence if they gain distribution through retailers like Walmart or Walgreens.

此外，这种合作关系有助于我们为产品名称注册商标，这些产品将按照当地法规作为膳食补充剂、营养保健品或维生素销售。这一战略举措对我们公司具有重要价值，因为某些维生素，如我们的癌症维生素a或癌前维生素a，如果通过沃尔玛或沃尔玛等零售商获得分销，可能会产生重大影响。

This highlights the critical importance of differentiating our products from those of competitors by trademarks..

这凸显了通过商标将我们的产品与竞争对手的产品区分开来的重要性。。

Initiatives like this infuse the company with a fresh and profound value. Conversely, a firm that disregards patenting, omits trademarking, dismisses valuation, and fails to form elite distributor partnerships essentially loses its worth. Therefore, every step taken, every seed planted, dramatically elevates the company's value..

这样的举措为公司注入了全新而深刻的价值。相反，一家无视专利、忽略商标、拒绝估值、未能与精英经销商建立合作关系的公司实际上失去了它的价值。因此，采取的每一步，种植的每一粒种子，都极大地提升了公司的价值。。

As CBIH continues to expand, we remain committed to investing time, effort, and thoughtful consideration into our endeavors that ultimately transform into revenues, predominantly because we cannot be a company that can't see the forest from the tree. Instead, we are gaining sustainable competitive advantage in the industry..

随着CBIH的不断扩张，我们仍然致力于投入时间、精力和深思熟虑的考虑，以最终转化为收入，主要是因为我们不能成为一家从树上看不到森林的公司。相反，我们正在行业中获得可持续的竞争优势。。

Each step we undertake lays the groundwork for future successes, mirroring the trajectory of companies that have transformed from modest beginnings to industry leaders. We are poised for a prosperous future, driven by various revenue generation centers, strategic partnerships, and continued growth.

我们采取的每一步都为未来的成功奠定了基础，反映了公司从最初的规模不大转变为行业领导者的轨迹。在各种创收中心、战略合作伙伴关系和持续增长的推动下，我们为繁荣的未来做好了准备。

FORWARD-LOOKING STATEMENTS

前瞻性声明

This press release may contain forward-looking statements. The words 'believe,' 'expect,' 'should,' 'intend,' 'estimate,' 'projects,' variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.

本新闻稿可能包含前瞻性声明。“相信”、“期望”、“应该”、“打算”、“估计”、“项目”等词语的变体和类似表达都可以识别前瞻性陈述，但它们的缺失并不意味着一个陈述不是一个前瞻性陈述。

These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

这些前瞻性陈述基于公司当前的预期，并受到许多风险、不确定性和假设的影响。公司没有义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。

Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com..

可能导致实际结果与此类前瞻性声明明示或暗示的结果存在显著差异的重要因素包括公司文件中详述的风险，这些文件可在www。OTCmarkets.com。。

For more information contact us at:

有关更多信息，请联系我们：

(214) 733-0868

ir@cbih.net

Dante Picazo

但丁·皮卡佐

CEO - CBIH

首席执行官-CBIH

Website: www.cbih.net

网址：www.cbih.net

X: www.twitter.com/cbihstock